Crohn's disease is a chronic inflammatory condition of the digestive tract caused by abnormal immune reactions. It is a form of inflammatory bowel disease and can affect any part of the gastrointestinal tract from mouth to anus. The disease often follows cycles of flares and remission.
Johnson & Johnson said Tremfya met the primary endpoint in the Phase 3 FUZION study in active perianal fistulizing Crohn’s disease. At Week 24, both Tremfya dosing regimens showed statistically significant combined fistula remission versus placebo.
Risankizumab data in Crohn’s disease showed 55% clinical remission at week 12 in AFFIRM, durable efficacy through 148 weeks in SEQUENCE, and the lowest 24-month switch rate in a U.S. claims analysis.
A retrospective real-world study of 108 Chinese patients with anti-TNF-refractory Crohn’s disease found upadacitinib clinical remission rates of 55.1% at week 12 and 52.5% at week 24.
AbbVie filed an sBLA for SKYRIZI as a subcutaneous induction therapy for Crohn's disease, supported by Phase 3 AFFIRM data. SKYRIZI and Rinvoq combined for $25.9B in 2025 revenue, exceeding 2027 guidance. The FDA also approved Venclexta plus acalabrutinib in CLL.
Eli Lilly, AbbVie, Vertex, Gilead Sciences and Pfizer were identified as pharmaceutical stocks to watch, with Abbott Laboratories and McKesson appearing on a separate seven-stock list.
AbbVie said Skyrizi and Rinvoq generated $26.0 billion in 2025 sales and are expected to exceed $31 billion in 2026. The company said the two immunology drugs continue to offset Humira erosion and drive top-line growth.
Crohn’s disease is linked to kidney stones, dehydration and rare serious kidney complications. Monitoring, hydration and attention to medication-related risks can help protect kidney health.
AbbVie has received a "Moderate Buy" consensus rating from analysts with an average price target of $253.15. The company reported strong quarterly earnings of $2.71 EPS and $16.62 billion revenue, beating estimates. Recent clinical progress includes positive Phase 1 results for an obesity drug candidate showing 7.8-9.8% weight loss.
Colorectal cancer rates are rising 3% annually in adults under 50, prompting expanded screening efforts and new treatment approaches. Recent research shows promise in combination immunotherapy and vaccine strategies for advanced disease.
AbbVie reported positive Phase 3 data for Skyrizi's subcutaneous Crohn's disease treatment and is advancing lutikizumab and Rinvoq in hidradenitis suppurativa, with multiple readouts expected throughout 2026 as the company pursues combination therapy strategies.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07555808 |
MRI-Based Screening in a Retrospective Cohort Reveals Adverse Prognosis of Asymptomatic Perianal Fistulas in Crohn's Disease: A Long-term Follow-Up Study |
COMPLETED | |
| NCT07545317 |
Real-World Study of IL-23 Inhibitors in Active Crohn's Disease |
RECRUITING | |
| NCT07531342 |
Repetitive Transcranial Magnetic Stimulation Combined With Anti-inflammatory Diet in Crohn's Disease |
NOT_YET_RECRUITING | NA |
| NCT07504510 |
Exclusive Enteral Nutrition Therapy for Active and Complicated Crohn's Disease |
RECRUITING | |
| NCT07421258 |
A Retrospective Study to Evaluate Treat-to-Target and Disease Modification in Adult Participants With Crohn's Disease and Ulcerative Colitis in Real World Setting |
RECRUITING | |
| NCT07417696 |
Palmitoleic Acid Combined With Infliximab for Promoting Intestinal Mucosal Healing in Crohn's Disease |
NOT_YET_RECRUITING | PHASE4 |
| NCT07403968 |
A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease |
NOT_YET_RECRUITING | PHASE2 |
| NCT07397195 |
ACT for Veterans With IBD and Mental Health Challenges |
NOT_YET_RECRUITING | NA |
| NCT07377188 |
Pregnancy and Inflammatory Bowel Disease |
RECRUITING | |
| NCT07315711 |
The Effect of Vascular Imaging Devices on Success Rates of Peripheral Vascular Access in Pediatric Patients |
NOT_YET_RECRUITING |
